Press releases
- Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC
- Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference
- Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors
- Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference
- Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
- Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 22.60 |
---|---|
High | 23.20 |
Low | 22.40 |
Bid | 22.40 |
Offer | 22.60 |
Previous close | 22.60 |
Average volume | 8.80 |
---|---|
Shares outstanding | 84.99m |
Free float | 83.42m |
P/E (TTM) | -- |
Market cap | 2.08bn USD |
EPS (TTM) | -3.22 USD |
Data delayed at least 15 minutes, as of Jul 26 2024.
More ▼